Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice
Wen Su,Sijin Wu,Yongliang Yang,Yanlin Guo,Haibo Zhang,Jie Su,Lei Chen,Zhuo Mao,Rongfeng Lan,Rong Cao,Chunjiong Wang,Hu Xu,Cong Zhang,Sha Li,Min Gao,Xiaocong Chen,Zhiyou Zheng,Bing Wang,Yi’ao Liu,Zuojun Liu,Zimei Wang,Baohua Liu,Xinmin Fan,Xiaoyan Zhang,Youfei Guan
DOI: https://doi.org/10.1038/s41467-022-34299-1
IF: 16.6
2022-11-02
Nature Communications
Abstract:Abstract 17β-hydroxysteroid dehydrogenase-13 is a hepatocyte-specific, lipid droplet-associated protein. A common loss-of-function variant of HSD17B13 (rs72613567: TA) protects patients against non-alcoholic fatty liver disease with underlying mechanism incompletely understood. In the present study, we identify the serine 33 of 17β-HSD13 as an evolutionally conserved PKA target site and its phosphorylation facilitates lipolysis by promoting its interaction with ATGL on lipid droplets. Targeted mutation of Ser33 to Ala (S33A) decreases ATGL-dependent lipolysis in cultured hepatocytes by reducing CGI-58-mediated ATGL activation. Importantly, a transgenic knock-in mouse strain carrying the HSD17B13 S33A mutation ( HSD17B13 33A/A ) spontaneously develops hepatic steatosis with reduced lipolysis and increased inflammation. Moreover, Hsd17B13 33A/A mice are more susceptible to high-fat diet-induced nonalcoholic steatohepatitis. Finally, we find reproterol, a potential 17β-HSD13 modulator and FDA-approved drug, confers a protection against nonalcoholic steatohepatitis via PKA-mediated Ser33 phosphorylation of 17β-HSD13. Therefore, targeting the Ser33 phosphorylation site could represent a potential approach to treat NASH.
multidisciplinary sciences